SCHEMBL5827796

SCHEMBL5827796

COC1C(O)[C@H](n2cnc3c(=O)[nH]c(N)nc32)O[C@@H]1COP(=O)(O)OP(=O)(O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.69
NT5E P21589 1/20 0.64
FUT5 Q11128 1/20 0.64
KRAS P01116 3/20 0.63
ENPP1 P22413 2/20 0.60
P2RY1 P47900 2/20 0.60
P2RY12 Q9H244 1/20 0.60
P2RY6 Q15077 2/20 0.59
P2RX3 P56373 2/20 0.59
P2RX1 P51575 1/20 0.59
P2RY11 Q96G91 1/20 0.59
P2RX4 Q99571 1/20 0.59
IMPDH2 P12268 3/20 0.59
IMPDH1 P20839 1/20 0.59
P2RY2 P41231 1/20 0.59
P2RY4 P51582 1/20 0.59
RNASEL Q05823 1/20 0.58
DCPS Q96C86 1/20 0.58
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5827788 1.00 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL29829660 0.99 TGM2 (0.68) TGM2NT5EFUT5KRASENPP1
SCHEMBL3187816 0.99 TGM2 (0.68) TGM2NT5EFUT5KRASENPP1
SCHEMBL15747229 0.99 TGM2 (0.68) TGM2NT5EFUT5KRASENPP1
SCHEMBL2030121 0.99 TGM2 (0.68) TGM2NT5EFUT5KRASENPP1
SCHEMBL21150343 0.94 TGM2 (0.68) TGM2NT5EFUT5KRASENPP1
SCHEMBL29093620 0.94 TGM2 (0.67) TGM2NT5EFUT5KRASENPP1
SCHEMBL18769060 0.94 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL21715305 0.93 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL21715304 0.93 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4276189-B1 INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2026-04-01 EP disclosed
EP-4717779-A2 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TriLink BioTechnologies, LLC (US) 2026-04-01 EP disclosed
EP-4424835-B1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2026-01-21 EP disclosed
US-12258369-B2 Compositions and methods for synthesizing 5′-capped RNAs TRILINK BIOTECHNOLOGIES, LLC (US) 2025-03-25 US disclosed
US-12103944-B2 Compositions and methods for synthesizing 5′-capped RNAs TRILINK BIOTECHNOLOGIES, LLC (US) 2024-10-01 US disclosed
EP-4424835-A2 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TriLink BioTechnologies, LLC (US) 2024-09-04 EP disclosed
US-20240158433-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES, LLC (US) 2024-05-16 US disclosed
US-20240140982-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES, LLC (US) 2024-05-02 US disclosed
EP-4104687-B1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5 -CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2024-01-31 EP disclosed
EP-3954225-B1 INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2023-11-22 EP disclosed
EP-3906789-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5 -CAPPED RNAS TriLink BioTechnologies, LLC (US) 2021-11-10 EP disclosed
EP-3352584-B1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2021-05-12 EP disclosed
EP-3352584-B1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES LLC (US) 2021-05-12 EP disclosed
US-10913768-B2 Compositions and methods for synthesizing 5′-capped RNAs TRILINK BIOTECHNOLOGIES, INC. (US) 2021-02-09 US disclosed
US-10519189-B2 Compositions and methods for synthesizing 5′-Capped RNAs TRILINK BIOTECHNOLOGIES, INC. (US) 2019-12-31 US disclosed
US-20190144490-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES, INC. (US) 2019-05-16 US disclosed
US-20180273576-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS TRILINK BIOTECHNOLOGIES, INC. (US) 2018-09-27 US disclosed
US-20060252115-A1 Synthesis and use of anti-reverse mRNA cap analogues DARZYNKIEWICZ EDWARD 2006-11-09 US disclosed
US-7074596-B2 Synthesis and use of anti-reverse mRNA cap analogues BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2006-07-11 US disclosed
US-20030194759-A1 Synthesis and use of anti-reverse mRBA cap analogues DARZYNKIEWICZ, EDWARD (PL) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252115-A1 Synthesis and use of anti-reverse mRNA cap analogues RNGTT, RNMT, CPSF6 TGM2 2476/4885NT5E 486/4885FUT5 1876/4885
US-20240140982-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS RNGTT, RNMT, NT5C3B TGM2 1420/4885NT5E 29/4885FUT5 263/4885
US-12258369-B2 Compositions and methods for synthesizing 5′-capped RNAs RNGTT, RNMT, NT5C3B TGM2 1409/4885NT5E 32/4885FUT5 274/4885
US-20180273576-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS RNGTT, RNMT, NT5C3B TGM2 1420/4885NT5E 29/4885FUT5 263/4885
US-10913768-B2 Compositions and methods for synthesizing 5′-capped RNAs RNGTT, RNMT, NT5C3B TGM2 1409/4885NT5E 32/4885FUT5 274/4885
US-10519189-B2 Compositions and methods for synthesizing 5′-Capped RNAs RNGTT, RNMT, NT5C3B TGM2 1409/4885NT5E 32/4885FUT5 274/4885
US-12103944-B2 Compositions and methods for synthesizing 5′-capped RNAs RNGTT, RNMT, NT5C3B TGM2 1409/4885NT5E 32/4885FUT5 274/4885
US-20190144490-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS RNGTT, RNMT, NT5C3B TGM2 1420/4885NT5E 29/4885FUT5 263/4885
US-20240158433-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS RNGTT, RNMT, NT5C3B TGM2 1420/4885NT5E 29/4885FUT5 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.